NDUFA4L2 promotes trastuzumab resistance in HER2-positive breast cancer.

ABSTRACT:

Background

Trastuzumab (Herceptin) is the key systemic therapy for HER2-positive breast cancer. However, the initial response rate is limited to approximately 50% in patients. Moreover, most patients, especially at an advanced stage, eventually develop acquired resistance. Understanding the mechanisms of trastuzumab resistance is crucial for achieving better treatment outcome in this group of patients.

Methods

A trastuzumab-resistant (TR) cell line was developed using the BT474 HER2-positive breast cancer cell line. Whole-transcriptome expression array was performed and the TR-related gene NDUFA4L2 was identified by differential expression analysis between BT474 and BT474-TR. Mitochondrial localization of NDUFA4L2 was confirmed by immunofluorescence and western blotting usin

SUBMITTER: Yuan Y 

PROVIDER: S-EPMC8256255 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature